A Phase 1 interventional study of RPH-104 and Sodium chloride Sterile Injection 0.9% w/v in Healthy, sponsored by R-Pharm. Completed at 1 site in Turkey. Open to participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-12-28.
Sponsored by R-Pharm · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this first in human study is to evaluate the safety and tolerability of RPH-104 in humans.
RPH-104 is a macromolecular compound with a molecular weight of 152.715 kilodalton (Data on file) and is capable of binding human interleukin-1 beta (IL-1β). It has also been shown in vitro to be a highly potent inhibitor of IL-1β signalling pathway, with low picomolar inhibitor activity. In this First in Human study, RPH-104 will be evaluated primarily for its safety and tolerability. In a phase I study conducted with health volunteers, a similar monoclonal antibody, canakinumab, was investigated in terms of pharmacokinetics and pharmacodynamics besides efficacy and safety. Similarly, this aimed to investigate effects of RPH-104 on selected pharmacodynamic parameters, including Anti-Drug Antibodies (ADA) along with obtaining first human data on pharmacokinetics of RPH-104 in humans will be investigated in the same study.
R-Pharm is the lead sponsor of 58 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A single dose of RPH-104 (4, 20, 40, 80 or 160 mg) will be administered subcutaneously.
Biological: RPH-104
A single 0.9% sodium chloride injection will be administered subcutaneously.
Other: Sodium chloride Sterile Injection 0.9% w/v
Anti-IL-1 Mab
Sterile saline solution
Adverse Events
Number of participants with study drug related adverse events
Time frame: Until 60 days after administration
Serious Adverse Events
Number of Participants with Study Drug Related Serious Adverse Events
Time frame: Until 60 days after administration
Respiratory Rate
Percentage of participants with abnormal respiratory rate. The normal respiration rate for an adult at rest is 12 to 20 breaths per minute.
Time frame: Until 30 days after administration
Blood Pressure
Percentage of participants with abnormal blood pressure. An optimal blood pressure level is a reading under 120/80 mmHg
Time frame: Until 30 days after administration
Oxygen Saturation
Percentage of participants with abnormal oxygen saturation. Normal pulse oximeter readings usually range from 95 to 100 percent. Values under 90 percent are considered low.
Time frame: Until 30 days after administration
Body Temperature
Percentage of participants with abnormal body temperature. Among adults, the average body temperature ranges from 97°F (36.1°C) to 99°F (37.2°C).
Time frame: Until 30 days after administration
Clinical Laboratory Tests
Percentage of participants with abnormal clinical laboratory tests. Normal laboratory ranges of the central laboratory were used.
Time frame: Until 30 days after administration
RPH-104 - Area Under the Curve (AUC)
Mean AUC 0-t (area under the concentration- time curve from time zero to day 30)
Time frame: Day 1, Day 2, Day3, Day 4, Day 5, Day 6, Day 9, Day 12, Day 15, Day 20, Day 25, Day 30
RPH-104 - Time to Maximum Concentration (Tmax)
Median Tmax. Definition of Tmax is time at which Cmax occurs.
Time frame: Day 1, Day 2, Day3, Day 4, Day 5, Day 6, Day 9, Day 12, Day 15, Day 20, Day 25, Day 30
RPH-104 - Elimination Half-life (t1/2)
Mean t½. Definition of t½ is terminal elimination half-life.
Time frame: Day 1, Day 2, Day3, Day 4, Day 5, Day 6, Day 9, Day 12, Day 15, Day 20, Day 25, Day 30
RPH-104 - Maximum Plasma Concentration (Cmax)
Mean Cmax. Highest concentration determined in the measuring interval.
Time frame: Day 1, Day 2, Day3, Day 4, Day 5, Day 6, Day 9, Day 12, Day 15, Day 20, Day 25, Day 30
| Milestone | Treatment | Placebo |
|---|---|---|
| Started | 25 | 10 |
| Completed | 25 | 10 |
| Not completed | 0 | 0 |
Number of participants with study drug related adverse events
| participants | Treatment | Placebo |
|---|---|---|
| Adverse Events | 0 | 0 |
Number of Participants with Study Drug Related Serious Adverse Events
| Participants | Treatment | Placebo |
|---|---|---|
| Serious Adverse Events | 0 | 0 |
Percentage of participants with abnormal respiratory rate. The normal respiration rate for an adult at rest is 12 to 20 breaths per minute.
| percentage of participants | Treatment | Placebo |
|---|---|---|
| Respiratory Rate | 0 | 0 |
Percentage of participants with abnormal blood pressure. An optimal blood pressure level is a reading under 120/80 mmHg
| percentage of participants | Treatment | Placebo |
|---|---|---|
| Blood Pressure | 0 | 0 |
Percentage of participants with abnormal oxygen saturation. Normal pulse oximeter readings usually range from 95 to 100 percent. Values under 90 percent are considered low.
| percentage of participants | Treatment | Placebo |
|---|---|---|
| Oxygen Saturation | 0 | 0 |
Percentage of participants with abnormal body temperature. Among adults, the average body temperature ranges from 97°F (36.1°C) to 99°F (37.2°C).
| percentage of participants | Treatment | Placebo |
|---|---|---|
| Body Temperature | 0 | 0 |
Percentage of participants with abnormal clinical laboratory tests. Normal laboratory ranges of the central laboratory were used.
| percentage of participants | Treatment | Placebo |
|---|---|---|
| Clinical Laboratory Tests | 0 | 0 |
Mean AUC 0-t (area under the concentration- time curve from time zero to day 30)
| hr*ng/mL | Treatment | Placebo |
|---|---|---|
| 4 mg | 74500 ± 24700 | 0 ± 0 |
| 20 mg | 430000 ± 95700 | 0 ± 0 |
| 40 mg | 661000 ± 158000 | 0 ± 0 |
| 80 mg | 1610000 ± 317000 | 0 ± 0 |
| 160 mg | 3390000 ± 1450000 | 0 ± 0 |
Median Tmax. Definition of Tmax is time at which Cmax occurs.
| hr | Treatment | Placebo |
|---|---|---|
| 4 mg | 96 (94.4 to 192) | 0 (0 to 0) |
| 20 mg | 96 (48 to 96.2) | 0 (0 to 0) |
| 40 mg | 120 (96.0 to 192) | 0 (0 to 0) |
| 80 mg | 96 (72.0 to 120) | 0 (0 to 0) |
| 160 mg | 120 (72.0 to 120) | 0 (0 to 0) |
Mean t½. Definition of t½ is terminal elimination half-life.
| hr | Treatment | Placebo |
|---|---|---|
| 4 mg | 245 ± 9.50 | 0 ± 0 |
| 20 mg | 249 ± 6.08 | 0 ± 0 |
| 40 mg | 255 ± 43.1 | 0 ± 0 |
| 80 mg | 235 ± 22.8 | 0 ± 0 |
| 160 mg | 243 ± 40.4 | 0 ± 0 |
Mean Cmax. Highest concentration determined in the measuring interval.
| ng/mL | Treatment | Placebo |
|---|---|---|
| 4 mg | 198 ± 89.1 | 0 ± 0 |
| 20 mg | 1280 ± 402 | 0 ± 0 |
| 40 mg | 1650 ± 257 | 0 ± 0 |
| 80 mg | 5120 ± 1410 | 0 ± 0 |
| 160 mg | 10300 ± 4470 | 0 ± 0 |
Collected over 60 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment | 0/25 (0%) | 0/25 (0%) | 22/25 (88%) |
| Placebo | 0/10 (0%) | 0/10 (0%) | 7/10 (70%) |
| Event | Treatment | Placebo |
|---|---|---|
| Nervous system disordersNervous system disorders | 13/25 | 4/10 |
| Gastrointestinal disordersGastrointestinal disorders | 8/25 | 4/10 |
| Infections and infestationsInfections and infestations | 6/25 | 3/10 |
| General disorders and administration site conditionsGeneral disorders | 3/25 | 2/10 |
| Musculoskeletal and connective tissue disordersMusculoskeletal and connective tissue disorders | 2/25 | 2/10 |
| Ear and labyrinth disordersEar and labyrinth disorders | 1/25 | 1/10 |
| Cardiac disordersCardiac disorders | 0/25 | 1/10 |
| Reproductive system and breast disordersReproductive system and breast disorders | 0/25 | 1/10 |
| Skin and subcutaneous tissue disordersSkin and subcutaneous tissue disorders | 2/25 | 0/10 |
| InvestigationsInvestigations | 2/25 | 0/10 |
All subjects receiving the study medication will be included into the safety evaluation. Subjects who completed the study according to the protocol (per protocol population) will be included into the statistical evaluation. Subject data of drop-out volunteers or volunteers who were not eligible for the study will not be included into statistics.
| Age, Customized(participants) | Treatment | Placebo | Total |
|---|---|---|---|
| 18-35 | 25 | 10 | 10 |
| Sex: Female, Male(Participants) | Treatment | Placebo | Total |
|---|---|---|---|
| Female | 2 | 1 | 3 |
| Male | 23 | 9 | 32 |
| Race and Ethnicity Not Collected(Participants) | Treatment | Placebo | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Region of Enrollment(Participants) | Treatment | Placebo | Total |
|---|---|---|---|
| Turkey | 25 | 10 | 35 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
The record gives a start of Jan 2016, a primary completion of Jun 2017 and a completion of Jun 2017. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2019, 2 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Goflikicept